Bristol-Myers Squibb Australia

What Bristol-Myers Squibb Australia does

Bristol-Myers Squibb Australia is the Australian operating subsidiary of Bristol-Myers Squibb Company, a United States-domiciled, NYSE-listed (ticker: BMY) global biopharmaceutical enterprise. Established in Australia in 1955, the entity has maintained a continuous local presence for 70 years as of 2025-2026, focused on bringing innovative prescription medicines to Australian patients across four principal therapeutic areas: immuno-oncology, cardiovascular disease (with particular emphasis on hypertrophic cardiomyopathy), hematology, and fibrotic diseases. The subsidiary's product portfolio is commercialized primarily through Australia's Pharmaceutical Benefits Scheme (PBS), with distribution routed through hospitals, specialist clinics, and community pharmacies. Pricing of PBS-listed medicines is not publicly disclosed at the product level, reflecting standard Australian reimbursement policy.

The Australian operations combine prescription pharmaceutical distribution with patient-facing educational platforms and clinical research infrastructure. Patient education assets include the immuno-oncology platform myio.com.au and the HCM-focused yourhcmmatters.com.au, both designed to support patients, caregivers, and healthcare providers. A dedicated Australia clinical trials portal (bmsclinicaltrials.com/au) enables researcher and partner engagement with the parent's ongoing clinical research programs in Australia. Customer segments are defined horizontally as patients and caregivers, healthcare providers (cardiologists and oncologists prominently), and researchers and partners. Reported local headcount is lean at seven employees, indicating a focused commercial and medical-affairs footprint that relies on the parent company's global R&D, manufacturing, regulatory, and back-office infrastructure rather than running independent local operations. A March 2026 multi-indication PBS listing for two immunotherapy treatments is the most significant recent commercial milestone and is expected to materially expand reimbursed patient access.

Name

Bristol-Myers Squibb Australia

Legal name

Bristol-Myers Squibb Company

Website

https://bmsa.com.au

Company type

Public

Founded year

1955

Operating status

Operating

Headcount range

1–10 employees

Short description

Bristol-Myers Squibb Australia is the Australian subsidiary of NYSE-listed Bristol-Myers Squibb Company, commercializing prescription biopharmaceuticals in immuno-oncology, cardiovascular (HCM), hematology, and fibrotic disease through the PBS to Australian healthcare providers and patients.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Biopharmaceutical medicines
• Immuno-oncology treatments
• Specialty pharmaceuticals
• Prescription drug portfolio
• Cardiovascular disease therapeutics

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Distribution channels1 record

Marketing channels3 records

Core offering

Bristol-Myers Squibb Australia develops, manufactures, and distributes a portfolio of prescription biopharmaceutical medicines in Australia, with a focus on immuno-oncology and specialty therapeutics such as treatments for cancer and hypertrophic cardiomyopathy. Products are made available to Australian patients primarily through the Pharmaceutical Benefits Scheme (PBS) via hospitals, specialist clinics, and community pharmacies. The company also operates patient education platforms and clinical trial programs supporting its therapeutic portfolio.

Product overview

Bristol-Myers Squibb Australia operates as a biopharmaceutical company offering a portfolio of prescription medicines across multiple therapeutic areas, supported by patient education platforms and clinical trial services. The core offering consists of 'Our Medicines' — a suite of pharmaceutical products including immunotherapy treatments — supplemented by patient support programs like the HCM Matters initiative and the immuno-oncology education platform (myio.com.au). Clinical trials services provide research access for healthcare partners. The company celebrated 70 years of operation in Australia in 2024/2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Our Medicines A portfolio of prescription biopharmaceutical medicines covering therapeutic areas including immuno-oncology, cardiovascular disease, hematology, and fibrotic diseases, made available in Australia through the PBS and supplied to healthcare providers, hospitals, and pharmacies.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Market position

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/bmsnews
• LinkedInlinkedin.com/company/bristol-myers-squibb-australia

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bristol-Myers Squibb Australia